论文部分内容阅读
目的观察疏血通联合依达拉奉治疗进展性脑卒中的疗效及血液流变学和纤维蛋白原变化及安全性。方法将86例进展性脑卒中患者,随机分为两组,观察组46例,基础治疗加疏血通注射液联合依达拉奉注射液治疗,对照组40例,基础治疗加丹参注射液治疗,治疗14d后观察疗效。结果观察组治疗14天d神经功能恢复明显高于对照组,血液流变学指标(全血比粘度、血浆比粘度、红细胞压积)和纤维蛋白原指标显著下降。结论疏血通联合依达拉奉能有效降低血液粘滞度,明显改善神经功能缺损症状,不良反应小。
Objective To observe the curative effect, hemorheology and fibrinogen change and safety of Shuxuetong combined with edaravone in patients with advanced stroke. Methods Totally 86 patients with progressive stroke were randomly divided into two groups. The observation group consisted of 46 patients with basic therapy and Shuxuetong injection combined with edaravone injection. The control group received 40 cases of basic treatment plus Salvia miltiorrhiza injection After 14 days of treatment, the curative effect was observed. Results The recovery of neurological function in observation group on day 14 was significantly higher than that in control group, and the indexes of hemorheology (whole blood specific viscosity, plasma specific viscosity, hematocrit) and fibrinogen index decreased significantly. Conclusion Shuxuetong combined edaravone can effectively reduce blood viscosity, significantly improve the symptoms of neurological deficits, adverse reactions.